inv(16), CBFB-MYH11 Translocation
Also known as: CBFB-MYH11 Fusion
Use
The assay detects and quantifies the CBFß (core binding factor ß chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts in bone marrow and peripheral blood in patients with acute myelomonocytic leukemia with abnormal eosinophils, M4E0.Which counts for approximately 10% of all acute myeloid leukemia (AML). Patients with inv (16) generally are associated with relatively good long-term, disease free survival. Confirmation of the diagnosis of this subtype of acute myeloid leukemia is very important due to its specific management. In addition to confirming diagnosis, this assay is also recommended for monitoring minimal residual disease (MRD) and predicting relapse.
Special Instructions
Not provided.
Limitations
This assay detects type A fusion transcript only. The inv (16) translocation produces five types of fusion transcript (A, B, C, D and E). The type A accounts for more than 90% of cases detected. Monitoring trends rather than the absolute ratio of a single measurement is recommended for MRD.
Methodology
PCR-based (RT-PCR)
Biomarkers
CBFB-MYH11 fusion
Fusion
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube
Storage Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible.